<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814372</url>
  </required_header>
  <id_info>
    <org_study_id>M102-20814</org_study_id>
    <nct_id>NCT00814372</nct_id>
  </id_info>
  <brief_title>Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin</brief_title>
  <official_title>A Phase 2 Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of MBX-102/JNJ-39659100 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CymaBay Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CymaBay Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To define the relative efficacy, safety and tolerability profiles of oral daily MBX-102 at
      daily doses of 400 and 600 mg vs. placebo and Actos® 30 mg (up-titrated to 45 mg after 8
      weeks) when administered for up to 24 weeks in patients inadequately controlled with a stable
      dose of metformin (≥ 1500 mg/day).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 240 patients will be randomized in this study, 60 to each of two MBX-102
      treatment groups (400 and 600 mg daily), 60 to placebo, and 60 to the Actos® group. Patients
      in the Actos® group will receive Actos® 30 mg/daily for the first eight weeks of the
      treatment phase and Actos® 45 mg/daily for the last 16 weeks of the treatment phase. Patients
      in the MBX-102 400 mg group and MBX-102 600 mg group will continue MBX-102 400 mg and 600 mg,
      respectively for the full 24 weeks. All study medication will be over-encapsulated; thus,
      each patient will take two blinded capsules each day containing either placebo, MBX-102 or
      Actos®. This sample size provides the minimum number expected to ensure a power of at least
      90% in detecting a difference of 0.64% in HbA1c between the placebo and experimental
      treatment, using a two-tailed, two-sample t-test with type 1 error of 0.05, when the pooled
      standard deviation is ≤ 1.0%, and the discontinuation rate is ≤ 12.5%.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    MBX-102 did not meet the target efficacy profile of HbA1c change.
  </why_stopped>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c from baseline and compared to placebo</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose (FPG) from baseline and vs. placebo</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>MBX-102 400</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MBX-102 600</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Actos</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30-45 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-102</intervention_name>
    <description>capsule</description>
    <arm_group_label>MBX-102 400</arm_group_label>
    <arm_group_label>MBX-102 600</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Actos</intervention_name>
    <description>over-encapsulated to match MBX-102 and placebo</description>
    <arm_group_label>Actos</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>greater than or equal to 1500 mg/kg day</description>
    <arm_group_label>MBX-102 400</arm_group_label>
    <arm_group_label>MBX-102 600</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Actos</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with type 2 diabetes who have been on metformin for the last 6 months and are
             taking a stable dose of metformin (≥ 1500 mg/d) as monotherapy for at least the last 3
             months

          -  Male or female, 18-70 years of age

          -  All female patients must be surgically sterile or post-menopausal (at least 40 years
             of age with no history of menses for at least 2 years; or any age with no history of
             menses for at least 6 months and serum FSH ≥ 40 mIU/mL) or must agree to use two
             medically accepted methods of contraception including a barrier method. Depo
             contraceptives are excluded.

          -  Female patients must not be pregnant or lactating

          -  BMI ≥ 26 (patients of Asian Indian origin ≥ 22) kg/m2

          -  HbA1c ≥ 7.5%, ≤ 10.5%

          -  FPG ≥ 120 mg/dL, ≤ 240 mg/dL

        Exclusion Criteria:

          -  History of diabetes secondary to pancreatitis or pancreatectomy

          -  Any history of ketoacidosis

          -  History of insulin use within last one year (insulin use while hospitalized is
             acceptable)

          -  Weight loss &gt; 10 pounds in the three months prior to screening visit

          -  History of TZD use (Actos® or Avandia®) within 6 months of screening visit

          -  History of TZD discontinuation due to side effect or lack of efficacy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Denham, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>dgd Research, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas W. Littlejohn, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Piedmont Medical Research Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Guice, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>American Institute of Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>K. M. Prasanna Kumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M. S. Ramaiah Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Veerasamy Seshiah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. V. Seshiah Diabetes Care &amp; Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sanjay Kalra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bharti Research Institute of Diabetes &amp; Endocrinology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sailesh Lodha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fortis Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ariachery C Ammini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>All India Institute of Medical Sciences, New Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prema Varthakavi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BYL Nair Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sanjiv Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Action Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manoj Chadha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PD Hindhuja National Hospital &amp; Medical Research Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mathew Thomas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Health &amp; Research Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sanjay Reddy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bangalore Diabetes Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ganapati Bantwal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Johns Medical College Hospital, Bangalore, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aravind S Sosale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diacon Hospital Diabetes &amp; Research Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vaishali Deshmukh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deenanath Mangeshkar Hospital &amp; Research Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abhay Mutha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Care &amp; Research Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nihal Thomas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christian Medical College, Vellore, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kirtikumar Modi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medwin Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sunil Jain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Thyroid Hormone Research Institute Pvt. Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pramod Gandhi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gandhi Endocrinology &amp; Diabetes Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rakesh Kumar Sahay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mediciti Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harish Kumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amrita Institute of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rubin Savedra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Association of International Professionals, dba Nevada Alliance Against Diabetes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teresa Sligh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Translational Research Group, Inc. dba Providence Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prabha Adhikari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kasturba Medical College Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Navneet Agrawal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes, Obesity and Thyroid Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Swamy Miryala, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kamineni Hospitals Pvt, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Providence Clinical Research</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Institute of Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Alliance Against Diabetes</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Medical Research Associates</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DGD Research, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kamineni Hospitals Pvt, Ltd.</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>50008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bangalore Diabetes Centre</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diacon Hospital Diabetes &amp; Research Centre</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M. S. Ramaiah Memorial Hospital</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Medical College &amp; Hospital</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. V. Seshiah Diabetes Care &amp; Research Institute</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mediciti Hospital</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medwin Hospital</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Thyroid Hormone Research Institute Pvt. Ltd.</name>
      <address>
        <city>Indore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fortis Hospital</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bharti Research Institute of Diabetes &amp; Endocrinology</name>
      <address>
        <city>Karnal</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amrita Institute of Medical Sciences</name>
      <address>
        <city>Kochi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Action Centre</name>
      <address>
        <city>Mumbai</city>
        <zip>400067</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BYL Nair Hospital</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PD Hindhuja National Hospital</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gandhi Endocrinology &amp; Diabetes Centre</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deenanath Mangeshkar Hospital &amp; Research Centre</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Care &amp; Research Centre</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health &amp; Research Centre</name>
      <address>
        <city>Trivendrum</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian Medical College</name>
      <address>
        <city>Vellore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2008</study_first_submitted>
  <study_first_submitted_qc>December 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2008</study_first_posted>
  <disposition_first_submitted>February 16, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 9, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 30, 2015</disposition_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

